Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA.
Breast Cancer (Dove Med Press). 2016 May 3;8:73-82. doi: 10.2147/BCTT.S97963. eCollection 2016.
There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and increases in bone loss. These negative effects on the bone can significantly impact morbidity and mortality. Effective management and minimization of bone-related complications in postmenopausal women with hormone receptor-positive breast cancer remain essential. This review discusses the current understanding of molecular and biological mechanisms involved in bone turnover and metastases, increased risk for bone-related complications from breast cancer and breast cancer therapy, and current and emerging treatment strategies for managing bone metastases and bone turnover in postmenopausal women with hormone receptor-positive breast cancer.
绝经后激素受体阳性乳腺癌患者存在发生骨丢失和骨骼相关事件（包括骨转移）的高风险。疾病本身及其治疗方法都会对骨骼产生负面影响，导致骨密度降低和骨丢失增加。这些对骨骼的负面影响会显著影响发病率和死亡率。有效管理和尽量减少绝经后激素受体阳性乳腺癌患者的骨骼相关并发症仍然至关重要。本文讨论了目前对骨转换和转移涉及的分子和生物学机制、乳腺癌和乳腺癌治疗引起的骨骼相关并发症风险增加的理解，以及管理绝经后激素受体阳性乳腺癌患者的骨骼转移和骨转换的现有和新兴治疗策略。
